PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.

CytoSorbents Corporation successfully closed an oversubscribed rights offering, raising $6.25 million in aggregate gross proceeds, which satisfies a debt covenant, unlocking $5 million in ...

CytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results. The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M ...

03, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood ...

PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

Analysts' ratings for CytoSorbents CTSO over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below offers a condensed view of their recent ratings, showcasing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...